Russian Association of Endocrinologists reports commencement of Trajenta clinical use

Russian Association of Endocrinologists, diabetes mellitus, DPP-4 inhibitor, linagliptin, Trajenta

1. Instruktsiya po meditsinskomu primeneniyu lekarstvennogo preparata Trazhenta (linagliptin), Beringer Ingel'khaim. LP- 001430-120112

2. Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on Glycemic control and markers of b-cell function in patients with inadequatelyc ontrolled type 2 diabetes: a randomized controlled trial.Diabetes Obes Metab. 2011 Mar;13(3):258-267.

3. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi K.A, Woerle HJ. Safety and efficacy of linagliptin as addon therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011 Jan;13(1):65-74.

4. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24 week randomized study. Diabet Med. 2011 Nov;28(11):1352-1361.

5. Rendell M, Chrysant SG, Emser A, Eynatten M von, Patel S, Trujillo A, Woerle HJ. Linagliptin effectively reduces blood glucose independent of age in patients with type 2 diabetes. ENDO 2011, 93rd Ann Mtg and Expo of the Endocrine Society, Boston, 4-7 Jun 2011. Endocr Rev. 2011;32(3). Abstr 3-497.

6. Patel S, Weber S, Emser A, Eynatten M von, Woerle HJ. Linagliptin improves glycaemic control independently of diabetes duration and insulin resistance in patients with type 2 diabetes. Abstracts of the 47th Annual Meeting of the EASD, Lisbon 2011. Diabetologia. 2011;54(Suppl. 1):S339. DOI: 10.1007/ s00125-011-2276-44.

7. Gallwitz B, Uhlig-Laske B, Battacharaya S, Patel S, Woerle H-J. Linagliptin has Improved Safety and Similar Efficacy to Glimepiride over 2 Years in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin. American Diabetes Association, 71th Scientific Sessions, San Diego, CA, June 24-28, 2011; 39-LB.

8. Schernthaner G, Barnett AH, Emser A, Patel S, Troost J, Woerle HJ, von Eynatten M. Safety and tolerability of linagliptin: a pooled analysis of data from 3572 patients with type 2 diabetes mellitus. ADA 71st Scientific Sessions, June 24-28, 2011

9. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovascular Diabetology 2012, 11:3